Specify Company / Ticker to Get the Summary
BioLineRx Ltd
BLRXBioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. Address: Modi?in Technology Park, Hevel Modi'in, Israel, 7177871
Analytics
WallStreet Target Price
4.57 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BLRX
Dividend Analytics BLRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BLRX
Stock Valuation BLRX
Financials BLRX
Results | 2019 | Dynamics |